AOD-9604 Side Effects & Safety: What the Evidence Shows

Peptide science · Side-effects series #15

AOD-9604 side effects are unusual to write about, because for a gray-market peptide it actually has a real human safety database — six placebo-controlled trials in roughly 900 people. The catch is that the database is narrow, comes from a single industry source, and studied a route of administration that is not the one people use today. It is also worth being upfront about the headline that marketing tends to skip: in its largest, longest trial the drug failed to beat placebo. This is an educational overview, not medical advice.

What AOD-9604 is

AOD-9604 (the name is short for “Anti-Obesity Drug”) is a synthetic 16-amino-acid fragment of the tail end of human growth hormone — the region around residues 176–191 that carries hGH lipolytic (fat-mobilizing) activity — with an extra tyrosine added at the front for stability. Its sequence is YLRIVQCRSVEGSCGF, with a disulfide bridge; the molecular formula is C₇₈H₁₂₃N₂₃O₂₃S₂, molecular weight about 1,815 g/mol, CAS 221231-10-3 (PubChem CID 71300630). It is closely related to, but not identical with, “hGH fragment 176-191.” It was developed by Metabolic Pharmaceuticals in Australia as an oral anti-obesity candidate, with the pitch that it could stimulate fat breakdown without the growth-signaling or insulin-resistance effects of full growth hormone — in mouse studies the lipolytic effect appeared to depend on beta-3 adrenergic receptors rather than the growth-hormone receptor.

What the human trials actually found

Six randomized, double-blind, placebo-controlled trials were run between 2001 and 2006 in roughly 900 obese but otherwise healthy adults. Crucially, every one of them dosed AOD-9604 orally (capsule) or by intravenous infusion — none tested the subcutaneous injection route sold online today.

On tolerability, the pooled analysis reported no treatment-related serious adverse events and no treatment-related dropouts. The most common complaint was mild-to-moderate headache, at rates similar to placebo. There was no significant rise in IGF-1 versus placebo, no deterioration in glucose or insulin handling, and no anti-drug antibodies detected — findings that broadly support the “does not act like growth hormone” claim, at least for those routes and durations.

On efficacy, the honest headline is failure. A 12-week trial found only about 1.8 kg more weight loss than placebo, and the larger 24-week trial showed no significant weight effect versus placebo. Obesity development was halted in 2007. In other words, the compound that is now marketed for fat loss did not meet its own weight-loss endpoint in the trial designed to prove it.

How to read that safety data honestly

The “well tolerated, no IGF-1 signal” conclusion is real, but three caveats keep it from being the reassurance it is often presented as. First, the entire safety database is single-source and industry-funded — written up by the developer, with no independent replication. Second, it covers oral and IV dosing; the safety of the injected product, of long-term use beyond 24 weeks, and of use in women of child-bearing potential or younger, non-obese adults was never studied. Third, “no adverse events reported” in modest trials is not the same as proven safety — a point that applies across this space, as discussed in our note on IGF-1 and growth-factor side effects. Treat the data as “no safety signal in these specific studies,” not as a clean bill of health for how the peptide is actually used.

Regulatory status: not approved, rejected for compounding, banned in sport

AOD-9604 was never approved as a drug anywhere; obesity development ended in 2007. In the United States it was reviewed for the 503A compounding bulk-drug list, and in December 2024 the FDA advisory committee voted against adding it, citing immunogenicity concerns (peptide aggregation and impurities) for the injectable route and inadequate human safety characterization for that use — so it is not a legal compounded medication. It is also prohibited in sport at all times by WADA under Category S0 (non-approved substances), and anti-doping labs have published methods to detect it. For the broader compounding picture, see FDA 503A categories explained, and for how a genuinely approved thymic peptide compares, see thymosin alpha-1.

The concrete real-world risk

Two practical literacy points follow from that: a certificate of analysis measures identity and purity, not sterility (see how to read a COA), and sterility and endotoxin are separate tests entirely (see endotoxins and the LAL test). Neither is addressed by a purity percentage.

Frequently asked questions

Does AOD-9604 raise IGF-1 like growth hormone?

In the company trials it did not significantly raise IGF-1 versus placebo. That was one of its selling points, but it was measured only for oral and IV dosing over up to 24 weeks.

Is AOD-9604 proven to cause weight loss?

No. Its 12-week trial showed only a small difference from placebo, and the larger 24-week trial found no significant weight effect — which is why development was stopped.

Is AOD-9604 legal or approved?

It is not an approved drug, and in December 2024 an FDA advisory committee voted against allowing it as a compounded medication. It is also banned in sport by WADA.

Is the “well tolerated” claim reliable?

It reflects real but single-source, industry-funded trials using oral/IV dosing. It does not cover the injected gray-market product, long-term use, or independent replication.

Informational only — not medical advice · 21+